Back
Science

Updated ACC/AHA Guidelines Lower LDL Thresholds and Recommend Earlier, More Personalized Cardiovascular Risk Assessment

Generated on: Last updated: 15 sources
View source

"The evidence is clear: achieving lower LDL levels leads to fewer heart attacks and strokes."

The 2026 ACC/AHA Cholesterol Guidelines: A Major Shift in Heart Disease Prevention

The American College of Cardiology (ACC) and the American Heart Association (AHA), along with nine other medical organizations, have released updated clinical guidelines for the management of dyslipidemia and cholesterol. Published jointly in Circulation and the Journal of the American College of Cardiology and presented at the ACC's 75th Annual Scientific Session, the 2026 Guideline on the Management of Dyslipidemia replaces the previous 2018 recommendations. The guidelines emphasize earlier screening, personalized risk assessment using a new calculator, and lower, more specific targets for low-density lipoprotein (LDL) cholesterol.

Earlier Screening and Risk Assessment

A major shift in the guidelines is the recommendation to begin cardiovascular risk assessment and cholesterol screening at a younger age.

  • Age for Initial Screening: The guidelines extend primary risk assessment to adults aged 30 to 79, a reduction from the previous starting age of 40.
  • Childhood Screening: Universal cholesterol screening is recommended for all children aged 9 to 11 and again at age 19 to detect conditions like familial hypercholesterolemia (FH). Screening is advised from age 2 for those with a family history of premature atherosclerotic cardiovascular disease (ASCVD) or FH.
  • Adults without known lipid disorders: Are advised to start periodic cholesterol checks at age 19.

The PREVENT Risk Calculator

The guidelines introduce the "Predicting Risk of Cardiovascular Disease EVENTs" (PREVENT) calculator as the standard tool for estimating risk. Developed using data from 6.6 million individuals, this calculator replaces previous models.

This new tool estimates both 10-year and 30-year risks of heart attack, stroke, and heart failure.

  • Data Inputs: The tool incorporates data from routine physicals, including blood sugar and kidney function.
  • Age Range: The 10-year risk is calculated for individuals aged 30 to 79, and the 30-year risk for those aged 30 to 59.
  • Updated Risk Categories: The 10-year risk categories are defined as:
    • Low: Less than 3%
    • Borderline: 3% to less than 5%
    • Intermediate: 5% to less than 10%
    • High: 10% or higher

Clearer LDL Cholesterol Targets

The guidelines reintroduce specific, lower targets for LDL cholesterol, stratified by patient risk level:

  • Low Risk (most people without risk factors): LDL below 100 mg/dL
  • Borderline or Intermediate Risk: LDL below 70 mg/dL
  • High Risk (existing heart disease, diabetes, advanced kidney disease): LDL below 55 mg/dL

These targets are based on evidence that achieving lower LDL levels leads to fewer heart attacks and strokes.

Individuals with a history of heart disease, diabetes, kidney disease, or significant family risk may be advised to aim for lower levels than previously recommended.

Expanded Biomarker Testing and Diagnostic Tools

The guidelines recommend the use of additional tests to refine risk assessment for patients when standard measures provide an incomplete picture:

  • Lipoprotein(a) (Lp(a)): A one-time blood test for all adults is now recommended. Lp(a) is a genetically inherited cholesterol particle. Elevated levels can increase heart risk by approximately 40% at moderate levels and up to twofold at extreme levels. While there are currently no specific treatments to lower Lp(a), testing helps identify patients at increased risk.
  • Apolipoprotein B (ApoB): Testing for ApoB, a measure of all artery-clogging particles, is suggested as an alternative to or in addition to LDL testing for individuals with high triglycerides, type 2 diabetes, or cardiovascular-kidney-metabolic syndrome.
  • Coronary Artery Calcium (CAC) Scan: This noninvasive CT scan is recommended for men aged 40 and older and women aged 45 and older who have a borderline or intermediate 10-year risk. It helps detect early arterial plaque buildup when treatment decisions are uncertain.

Treatment Recommendations

The updated guidelines provide a structured approach to treatment based on risk assessment.

  • First-Line Therapy: Statins remain the primary pharmacological treatment. For adults aged 30 and older with LDL cholesterol levels of 160 mg/dL or higher, medication may be considered, especially if lifestyle changes are insufficient.
  • Treatment Escalation: If LDL targets are not met with statins, doctors may add ezetimibe, bempedoic acid, or injectable therapies such as PCSK9 inhibitors. The guidelines recommend a faster escalation of therapy compared to the 2018 guidelines.
  • Initiating Therapy: Moderate-intensity statin therapy is recommended for those with a 10-year PREVENT-ASCVD estimate of 5% to less than 10% (intermediate risk).
  • Dietary Supplements: Not recommended for LDL reduction due to insufficient evidence.

Lifestyle Modifications

The guidelines continue to emphasize lifestyle as the foundation of cardiovascular prevention. The core recommendations include:

  • A heart-healthy diet, prioritizing whole foods over ultra-processed options.
  • Regular physical activity, aiming for at least 150 minutes of moderate exercise per week.
  • Avoiding tobacco products.
  • Maintaining quality sleep.
  • Achieving and sustaining a healthy weight and controlling blood pressure.

Risk Enhancers

The guidelines list several factors that can augment risk calculation, including family history of early heart disease, chronic inflammatory conditions (e.g., lupus, rheumatoid arthritis), chronic kidney disease, HIV, cancer, and specific reproductive conditions. For women, factors such as early premature menopause, preeclampsia, gestational diabetes, or hypertension during pregnancy are noted as risk enhancers.

Hypertriglyceridemia Treatment

The guidelines include specific recommendations for managing very high triglycerides (above 500 mg/dL), which can indicate a risk for pancreatitis. Newer treatments such as olezarsen and plozasiran are mentioned for significant triglyceride reduction.

Future Outlook

An accompanying editorial notes that the VESALIUS-CV clinical trial results may influence future guidelines.

The trial, which involved intensive LDL-C lowering with evolocumab in high-risk patients without prior stroke or MI, showed significant risk reductions. Future updates may consider a unified care pathway for all ASCVD patients, aiming for an optimal LDL-C level of 55 mg/dL or lower, and expanded recommendations for individuals with subclinical atherosclerosis.